Fig. 4.

Persisting antidrug antibody [ADAs] (n = 29) and neutralizing antibodies [Nabs] (n = 16) by previous enzyme replacement therapy status. For patients with more than one positive or negative result for ADA/NAb, patients with persisting ADAs/NAbs were defined as those with a positive antibody titer at the time of testing and at the previous sampling. Other treatment included agalsidase alfa (roller bottle [RB] or animal component-free) and agalsidase beta, those who had received agalsidase alfa RB and agalsidase alfa animal component-free, and those whose enzyme replacement therapy status was unknown